New drug AUR103 calcium targets Hard-to-Treat neuroendocrine tumors
Disease control
Not yet recruiting
This phase 2 study tests a new drug, AUR103 calcium, in 30 adults with advanced neuroendocrine tumors that have worsened after at least one prior treatment. Participants take the drug twice daily until their disease gets worse or side effects become too severe. The main goal is t…
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC